Cancer Diagnostics
Cancer Diagnostics - Related Videos
08:53
In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
0 Views •
Cited by 1 •
2019
The in vivo immunofluorescence localization (IVIL) method can be used to examine in vivo biodistribution of antibodies and antibody conjugates for oncological purposes in living organisms using a combination of in vivo tumor targeting and ex vivo immunostaining methods.
21:15
Diagnostic Necropsy and Tissue Harvest
0 Views •
2016
Source: Kay Stewart, RVT, RLATG, CMAR; Valerie A. Schroeder, RVT, RLATG. University of Notre Dame, IN Many animal experiments rely on final data collection time points that are gathered from the harvesting and testing of organs and tissues. The use of appropriate methods for the collection of organs and tissues can impact the quality of the samples and the analysis of the data that is gleaned for the testing of the tissues. The method of euthanasia of the animal can also impact the quality of...
07:16
Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
0 Views •
Cited by 6 •
2014
The isolation of cancer stem cells (CSCs) directly from human tissues is requisite for their biological characterization. This manuscript describes a methodology for the isolation of prostate CSCs from human tissues, while also providing tips on troubleshooting difficult steps.
16:05
Using Micro-Electro-Mechanical Systems (MEMS) to Develop Diagnostic Tools
0 Views •
Cited by 1 •
2007
10:21
Microfluidic Applications for Disposable Diagnostics
0 Views •
Cited by 1 •
2008
In this interview, Dr. Klapperich discusses the fabrication of thermoplastic microfluidic devices and their application for development of new diagnostics.
FAQs
Antibody-based tests add a molecular layer to cancer assessment by recognizing tumor-associated molecules. This recognition can support immunodiagnostic evaluation alongside tissue and laboratory analysis, while other assays measure immune responses. These readouts help characterize tumor biology and can contribute to classification or treatment decisions when interpreted with broader clinical findings.
Each type of evidence describes cancer from a different biological perspective. Cellular morphology shows features visible in cells or tissue, genetic assays identify alterations, and protein analysis reveals molecular characteristics. Combining these findings can provide a more complete basis for identifying tumor type, characterizing its biology, and supporting treatment decisions.
Immune-related biomarkers provide information about immune responses associated with a suspected or established cancer. They complement morphology, genetic, and protein-based findings rather than replacing them. Their value lies in adding immunological context to tumor characterization, which can support more precise classification and help inform how clinicians interpret the overall diagnostic picture.
The process begins with medical history and physical examination, followed by selected imaging, tissue biopsy, cytology, or laboratory assays. These methods supply progressively different kinds of evidence, from anatomical findings to cellular and molecular information. Clinicians combine the results to identify the cancer type and stage and to distinguish malignant from benign conditions.
Diagnostic findings help determine both what type of cancer is present and how advanced it is. Tissue, cytology, imaging, and laboratory results can also reveal characteristics of tumor biology or immune activity. Together, these data provide a basis for selecting and refining treatment decisions rather than relying on a single test result.
Molecular and immune profiling extends classification beyond appearance alone. Genetic alterations, protein patterns, and immune-related biomarkers can add information about tumor biology that may not be evident from morphology. This expanded characterization supports more precise cancer classification and contributes to increasingly personalized care when integrated with clinical and pathological findings.
Cancer findings can overlap with conditions that are benign or infectious, so diagnosis must address these alternatives. Imaging, tissue examination, cytology, and laboratory assays provide complementary evidence, while immunodiagnostic tests can assess tumor-associated molecules or immune responses. Integrating these results helps clinicians distinguish malignancy from infection and interpret immune-related findings in context.